CMR DENSE and the Seattle Heart Failure Model Inform Survival and Arrhythmia Risk After CRT.


Journal

JACC. Cardiovascular imaging
ISSN: 1876-7591
Titre abrégé: JACC Cardiovasc Imaging
Pays: United States
ID NLM: 101467978

Informations de publication

Date de publication:
04 2020
Historique:
received: 25 06 2019
revised: 23 09 2019
accepted: 10 10 2019
pubmed: 23 12 2019
medline: 6 1 2021
entrez: 23 12 2019
Statut: ppublish

Résumé

This study sought to determine if combining the Seattle Heart Failure Model (SHFM-D) and cardiac magnetic resonance (CMR) provides complementary prognostic data for patients with cardiac resynchronization therapy (CRT) defibrillators. The SHFM-D is among the most widely used risk stratification models for overall survival in patients with heart failure and implantable cardioverter-defibrillators (ICDs), and CMR provides highly detailed information regarding cardiac structure and function. CMR Displacement Encoding with Stimulated Echoes (DENSE) strain imaging was used to generate the circumferential uniformity ratio estimate with singular value decomposition (CURE-SVD) circumferential strain dyssynchrony parameter, and the SHFM-D was determined from clinical parameters. Multivariable Cox proportional hazards regression was used to determine adjusted hazard ratios and time-dependent areas under the curve for the primary endpoint of death, heart transplantation, left ventricular assist device, or appropriate ICD therapies. The cohort consisted of 100 patients (65.5 [interquartile range 57.7 to 72.7] years; 29% female), of whom 47% had the primary clinical endpoint and 18% had appropriate ICD therapies during a median follow-up of 5.3 years. CURE-SVD and the SHFM-D were independently associated with the primary endpoint (SHFM-D: hazard ratio: 1.47/SD; 95% confidence interval: 1.06 to 2.03; p = 0.02) (CURE-SVD: hazard ratio: 1.54/SD; 95% confidence interval: 1.12 to 2.11; p = 0.009). Furthermore, a favorable prognostic group (Group A, with CURE-SVD <0.60 and SHFM-D <0.70) comprising approximately one-third of the patients had a very low rate of appropriate ICD therapies (1.5% per year) and a greater (90%) 4-year survival compared with Group B (CURE-SVD ≥0.60 or SHFM-D ≥0.70) patients (p = 0.02). CURE-SVD with DENSE had a stronger correlation with CRT response (r = -0.57; p < 0.0001) than CURE-SVD with feature tracking (r = -0.28; p = 0.004). A combined approach to risk stratification using CMR DENSE strain imaging and a widely used clinical risk model, the SHFM-D, proved to be effective in this cohort of patients referred for CRT defibrillators. The combined use of CMR and clinical risk models represents a promising and novel paradigm to inform prognosis and device selection in the future.

Sections du résumé

OBJECTIVES
This study sought to determine if combining the Seattle Heart Failure Model (SHFM-D) and cardiac magnetic resonance (CMR) provides complementary prognostic data for patients with cardiac resynchronization therapy (CRT) defibrillators.
BACKGROUND
The SHFM-D is among the most widely used risk stratification models for overall survival in patients with heart failure and implantable cardioverter-defibrillators (ICDs), and CMR provides highly detailed information regarding cardiac structure and function.
METHODS
CMR Displacement Encoding with Stimulated Echoes (DENSE) strain imaging was used to generate the circumferential uniformity ratio estimate with singular value decomposition (CURE-SVD) circumferential strain dyssynchrony parameter, and the SHFM-D was determined from clinical parameters. Multivariable Cox proportional hazards regression was used to determine adjusted hazard ratios and time-dependent areas under the curve for the primary endpoint of death, heart transplantation, left ventricular assist device, or appropriate ICD therapies.
RESULTS
The cohort consisted of 100 patients (65.5 [interquartile range 57.7 to 72.7] years; 29% female), of whom 47% had the primary clinical endpoint and 18% had appropriate ICD therapies during a median follow-up of 5.3 years. CURE-SVD and the SHFM-D were independently associated with the primary endpoint (SHFM-D: hazard ratio: 1.47/SD; 95% confidence interval: 1.06 to 2.03; p = 0.02) (CURE-SVD: hazard ratio: 1.54/SD; 95% confidence interval: 1.12 to 2.11; p = 0.009). Furthermore, a favorable prognostic group (Group A, with CURE-SVD <0.60 and SHFM-D <0.70) comprising approximately one-third of the patients had a very low rate of appropriate ICD therapies (1.5% per year) and a greater (90%) 4-year survival compared with Group B (CURE-SVD ≥0.60 or SHFM-D ≥0.70) patients (p = 0.02). CURE-SVD with DENSE had a stronger correlation with CRT response (r = -0.57; p < 0.0001) than CURE-SVD with feature tracking (r = -0.28; p = 0.004).
CONCLUSIONS
A combined approach to risk stratification using CMR DENSE strain imaging and a widely used clinical risk model, the SHFM-D, proved to be effective in this cohort of patients referred for CRT defibrillators. The combined use of CMR and clinical risk models represents a promising and novel paradigm to inform prognosis and device selection in the future.

Identifiants

pubmed: 31864974
pii: S1936-878X(19)31015-0
doi: 10.1016/j.jcmg.2019.10.017
pmc: PMC7774038
mid: NIHMS1656140
pii:
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

924-936

Subventions

Organisme : NHLBI NIH HHS
ID : R21 HL140445
Pays : United States
Organisme : NHLBI NIH HHS
ID : R56 HL135556
Pays : United States

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2020 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Références

Heart Rhythm. 2013 Apr;10(4):e59-65
pubmed: 23403056
J Cardiovasc Magn Reson. 2018 Sep 13;20(1):63
pubmed: 30208894
Circ Cardiovasc Genet. 2009 Aug;2(4):371-8
pubmed: 20031609
J Am Coll Cardiol. 2017 May 30;69(21):2606-2618
pubmed: 28545633
Magn Reson Med. 2010 Oct;64(4):1089-97
pubmed: 20574967
Circulation. 2007 Jul 24;116(4):392-8
pubmed: 17620506
Circulation. 2019 Jul 23;140(4):293-302
pubmed: 31155932
Circulation. 2009 Sep 8;120(10):835-42
pubmed: 19704100
Med Image Anal. 2009 Feb;13(1):105-15
pubmed: 18706851
Am J Cardiol. 2012 Aug 1;110(3):398-402
pubmed: 22516524
Radiology. 2004 Mar;230(3):862-71
pubmed: 14739307
Radiology. 2019 Feb;290(2):329-337
pubmed: 30457480
Biometrics. 2000 Jun;56(2):337-44
pubmed: 10877287
IEEE Trans Med Imaging. 2007 Jan;26(1):15-30
pubmed: 17243581
J Am Coll Cardiol. 2013 Jan 22;61(3):e6-75
pubmed: 23265327
Radiology. 2015 May;275(2):413-20
pubmed: 25581423
Circulation. 2006 Mar 21;113(11):1424-33
pubmed: 16534009
Magn Reson Imaging. 2017 Jan;35:148-153
pubmed: 27569367
JACC Cardiovasc Imaging. 2015 Dec;8(12):1465-1466
pubmed: 25577442
Biometrics. 1988 Sep;44(3):837-45
pubmed: 3203132
Magn Reson Med. 2012 Jun;67(6):1590-9
pubmed: 22135133

Auteurs

Kenneth C Bilchick (KC)

Department of Medicine, University of Virginia Health System, Charlottesville, Virginia. Electronic address: bilchick@virginia.edu.

Daniel A Auger (DA)

Department of Biomedical Engineering, University of Virginia Health System, Charlottesville, Virginia.

Mohammad Abdishektaei (M)

Department of Biomedical Engineering, University of Virginia Health System, Charlottesville, Virginia.

Roshin Mathew (R)

Department of Medicine, University of Virginia Health System, Charlottesville, Virginia.

Min-Woong Sohn (MW)

Department of Public Health Sciences, University of Virginia Health System, Charlottesville, Virginia.

Xiaoying Cai (X)

Department of Biomedical Engineering, University of Virginia Health System, Charlottesville, Virginia.

Changyu Sun (C)

Department of Biomedical Engineering, University of Virginia Health System, Charlottesville, Virginia.

Aditya Narayan (A)

Department of Biomedical Engineering, University of Virginia Health System, Charlottesville, Virginia.

Rohit Malhotra (R)

Department of Medicine, University of Virginia Health System, Charlottesville, Virginia.

Andrew Darby (A)

Department of Medicine, University of Virginia Health System, Charlottesville, Virginia.

J Michael Mangrum (JM)

Department of Medicine, University of Virginia Health System, Charlottesville, Virginia.

Nishaki Mehta (N)

Department of Medicine, University of Virginia Health System, Charlottesville, Virginia.

John Ferguson (J)

Department of Medicine, University of Virginia Health System, Charlottesville, Virginia.

Sula Mazimba (S)

Department of Medicine, University of Virginia Health System, Charlottesville, Virginia.

Pamela K Mason (PK)

Department of Medicine, University of Virginia Health System, Charlottesville, Virginia.

Christopher M Kramer (CM)

Department of Medicine, University of Virginia Health System, Charlottesville, Virginia; Department of Radiology and Medical Imaging, University of Virginia Health System, Charlottesville, Virginia.

Wayne C Levy (WC)

Department of Medicine, University of Washington, Seattle, Washington.

Frederick H Epstein (FH)

Department of Biomedical Engineering, University of Virginia Health System, Charlottesville, Virginia; Department of Radiology and Medical Imaging, University of Virginia Health System, Charlottesville, Virginia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH